Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How do you sequence ADT relative to radiation for a low volume M1 prostate cancer?
Concurrent? Neoadjuvant and concurrent? If neoadjuvant, how long before?
Answer from: Radiation Oncologist at Community Practice
Start with radiotherapy, carry on hormone therapy for up to two years.
Sign in or Register to read more
6638
Related Questions
What radiation treatments would you offer an older man with unfavorable intermediate-risk prostate cancer, with comorbid conditions, if you don't feel he is a good candidate for full-course radiation therapy with ADT?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
How would you manage sarcomatoid carcinoma of the prostate with poorly differentiated adenocarcinoma that is not amenable to surgery?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?
How would you treat a patient with retroperitoneal lymphadenopathy that has been biopsy proven metastatic seminoma, who is not a candidate for orchiectomy, RPLND, or systemic therapy?